India Medtronic Private Limited, a wholly owned subsidiary of Medtronic plc — a global leader in healthcare technology, announced the launch of MiniMed 780G system in India. The MiniMed 780G system is a next generation closed loop insulin pump system for the treatment of type 1 diabetes in people aged 7 to 80 years.
The MiniMed 780G system enables the personalization of glucose goals with an adjustable target setting as low as 100 mg/dL — lower than any other advanced hybrid closed loop system — and is designed to help stabilize blood sugar levels and further improve glucose control. Patients who participated in a clinical study provided feedback that the MiniMed 780G system “made life with diabetes and control so much easier” and that it made “life significantly easier.”
The system is part of the new Medtronic portfolio of insulin pumps with smartphone connectivity via Bluetooth technology. This advancement allows users and their care partners to see real-time glucose data and trends on compatible iOS and Android smartphones via apps. Additionally, healthcare providers will find that managing patients on the system is simple as there are only a few settings that need adjustment to enable optimal use of the technology.
Clinical consensus regarding Time in Range means that a person living with diabetes should be in the recommended range of 70-180 mg/dL (3.9 – 10 mmol/L) for at least 70 per cent of time to be well-controlled. This may increase the likelihood that short and long-term complications of this chronic disease can be avoided.